10 April 2024 in Head & Neck
Background: Transoral robotic surgery (TORS) for oropharyngeal malignancy optimizes oncologic outcomes while preserving functionality. This study identifies patterns of functional recovery after TORS with free flap reconstruction (FFR).Methods: Retrospective cohort study at a tertiary care center of patients with primary oropharyngeal tumors treated with TORS with FFR between 2010 and 2022. Patients were categorized into: adjuvant chemoradiation or radiation, or no adjuvant therapy (NAT). Functional outcomes were measured by functional oral intake scale (FOIS).Results: 241 patients were included. FOIS declined at first postoperative appointment (median = 7.0 to 2.0, IQR = [7.0, 7.0], [2.0, 4.0]), and progressively improved to 6.0 (5.0, 6.0) after 1 year, with NAT having the highest FOIS (7.0, p < 0.05). Predictors of poor long‐term FOIS included RT and hypoglossal nerve (CN XII) involvement (p < 0.05).Conclusions: TORS with FFR leads to good long‐term function with minimal intake restrictions. Radiation therapy and CN XII involvement increase risk of worse functional outcomes.
11 March 2025 in Otolaryngology–Head and Neck Surgery
Objective: In the unique clinical context of a retropharyngeal carotid artery (RPC), free flap reconstruction (FFR) may be used for small pathologic tumor (pT)1‐2 human papillomavirus (HPV)+ oropharyngeal squamous cell carcinoma (OPSCC) tumors to provide vessel coverage, providing a unique case‐control study model. This study aims to elucidate the impact of FFR on functional outcomes following transoral robotic surgery (TORS).Study Design: Retrospective review of electronic medical records between 2010 and 2022.Setting: Single‐institution tertiary care center.Methods: Cohorts were defined as FFR (with RPC) and no FFR (nFFR). A 1:2 propensity score match (PSM) was performed. The functional oral intake scale (FOIS) was used to characterize swallowing outcomes. Statistical analysis was performed in R‐Studio.Results: Post‐PSM, 93 patients met inclusion criteria (59.8 years, 92% white, 88% male). In total, 31 (33%) underwent FFR, 77 (83%) had pT2 tumors, and 87 (93%) underwent adjuvant treatment. The FFR cohort saw increased return to the operating room (FFR 19% vs nFFR 3.3%, P < .001) and mean hospital stay (7.2 ± 2.2 vs 4.9 ± 3.1 days, P = .02). Median preoperative FOIS was similar between groups (FFR: 7.00 [interquartile range (IQR) 6.00‐7.00] vs nFFR: 7.0 [7.00‐7.00], P = .2) with comparable decline at first follow‐up. The nFFR cohort had higher FOIS at 3 and 6 months (5.00 [5.00‐6.00] vs 6.00 [5.00‐7.00], P = .04). FOIS was similar after 1 year (6.00 [5.00‐7.00] vs 6.00 [6.00‐7.00], P = .3).Conclusion: FFR achieved comparable functional outcomes to nFFR at 1 year. FFR is a viable reconstructive option for pT1‐2 tumors for which TORS that are amenable to surgical resection via TORS despite an anatomic barrier such as RPC.
30 December 2024 in Head & Neck
29 May 2025 in Otolaryngology–Head and Neck Surgery
Objective: Obesity is a well‐established risk factor for obstructive sleep apnea (OSA), and weight loss is often recommended alongside hypoglossal nerve stimulation (HGNS) in continuous positive airway pressure‐intolerant patients. Our study assesses how long‐term changes in body mass index (BMI) following HGNS impact surgical success.Study Design: A retrospective case review.Methods: We performed a retrospective case review of OSA patients who underwent HGNS at our institution from 2017 to 2022 and multicenter prospective patient data from the ADHERE registry. Patients were included if they had pre‐ and postoperative sleep studies and BMI data 1 year following surgery, and postsurgical outcomes were evaluated. Patients were stratified into 3 cohorts based on their BMI change from baseline to final follow‐up following surgery: (1) remaining within 2 BMI points, (2) gaining at least 2 BMI points, or (3) losing at least 2 BMI points.Results: In both institutional cohort (N = 222) and ADHERE cohort (N = 1949), most of the patients remained within 2 BMI points after HGNS (84.1% and 80.8%, respectively). The patients who lost at least 2 BMI points had the greatest reduction in AHI (−24.77 ± 13.84, −22.58 ± 19.76 events/h) compared to patients who maintained stable BMI (−15.10 ± 20.33, −18.85 ± 18.11 events/h) or gained at least 2+ BMI points (−6.39 ± 22.52, −15.82 ± 19.63 events/h) following HGNS (P = .002 and .006, respectively).Conclusions: While HGNS effectively reduces AHI, this effect was most significant in patients who experienced weight loss compared to those who gained or remained in stable body weight. Our study underscores the importance of postoperative weight management and its adjunctive role in improving HGNS success in OSA patients.
21 April 2025 in Otolaryngology–Head and Neck Surgery
Objective: To investigate the survival benefit of elective neck dissection (END) over neck observation in surgically resected cT1‐4 N0M0 head and neck spindle cell carcinoma (HNSpCC).Study Design: Retrospective cohort study.Setting: The 2006 to 2018 hospital‐based National Cancer Database (NCDB).Methods: Patients with surgically resected cT1‐4 N0M0 HNSpCC were selected. Linear, binary logistic, Kaplan‐Meier, and Cox proportional hazards regression models were implemented.Results: Of 815 patients satisfying inclusion criteria, a high proportion were male (72.4%) and white (86.0%) with disease of the larynx (43.8%) classified as high grade (87.7%) and cT1‐2 (74.8%). In total, 235 (28.8%) patients underwent END. END utilization between 2006 and 2018 increased for cT1‐2 disease (4.0% vs 30.5%, R2 = 0.731) and for cT3‐4 disease (15.4% vs 84.6%, R2 = 0.606). In total, 58 (24.7%) ENDs detected occult nodal metastases (ONMs). The 5‐year overall survival (OS) of patients undergoing neck observation and END was 62% and 54%, respectively (P = .215). Among patients undergoing END, patients with ONM had worse 5‐year OS than those without ONM (38% vs 60%, P < .001). On multivariable Cox regression, END was not associated with OS (adjusted hazard ratio [aHR] 0.74, 95% CI 0.68‐1.32, P = .735); ONM (hazard ratio [HR] 2.01, 95% CI 1.29‐3.12, P = .002) was associated with worse OS.Conclusion: END is performed in a high proportion (30%) of patients with cN0M0 HNSpCC but is not associated with higher OS. The rate of ONM approaching 25% and the association between ONM and worse OS, however, justify consideration of END in HNSpCC.Level of Evidence: 4.
24 September 2024 in The Laryngoscope
Objective: Undergoing surgery and adjuvant radiotherapy (aRT) at the same facility has been associated with higher overall survival (OS) in head and neck squamous cell carcinoma. Our study investigates whether undergoing surgery and aRT at the same academic facility is associated with higher OS compared with separate facilities in sinonasal squamous cell carcinoma (SNSCC).Methods: The 2006 to 2017 National Cancer Database was queried for patients with SNSCC undergoing surgery at an academic facility followed by aRT with or without adjuvant chemotherapy. Multivariable binary logistic and Cox proportional hazards regression models were implemented.Results: Of 419 patients satisfying inclusion criteria, 299 (71.4%) underwent surgery and aRT at the same academic facility. Residence in a less populated area (adjusted odds ratio [aOR] 1.75, 95% confidence interval [CI] 1.02–2.99, p = 0.042) and surgical facility case volume (aOR 2.51, 95% CI 1.21–5.21, p = 0.014) were associated with undergoing surgery and aRT at different facilities on multivariable logistic regression adjusting for patient demographics, clinicopathologic features, and adjuvant therapy (p < 0.05). Five‐year OS was higher among patients undergoing surgery and aRT at the same academic facility (64% vs. 55%, p = 0.039). Undergoing surgery and aRT at different facilities remained associated with worse OS on multivariable Cox regression (aHR 1.90, 95% CI 1.09–3.32, p = 0.023).Conclusion: Undergoing surgery and aRT at the same academic facility is associated with higher OS in SNSCC. Academic physicians should carefully consider the recommendation of aRT treatment facility based on the level of benefit that the patient may derive from coordinated multidisciplinary care.Level of Evidence: 3 Laryngoscope, 135:705–715, 2025